Dementia with Lewy Bodies (DLB) Cure Roadmap provides a comprehensive framework for therapeutic development for DLB, the second most common neurodegenerative dementia. DLB is characterized by alpha-synuclein pathology (Lewy bodies and Lewy neurites) affecting cortical and subcortical structures, producing a distinctive clinical syndrome including cognitive fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder[1].
Unlike Alzheimer's disease (AD), DLB involves prominent dysfunction in subcortical arousal systems — particularly the cholinergic nucleus basalis of Meynert and noradrenergic locus coeruleus — which explain the dramatic cognitive fluctuations unique to DLB[2].
| Drug | Indication | Mechanism | Evidence |
|---|---|---|---|
| Donepezil, Rivastigmine | DLB cognitive symptoms | Cholinesterase inhibition | Moderate (改善认知功能)[3] |
| Memantine | DLB (off-label) | NMDA antagonism | Limited |
| Levodopa | DLB parkinsonism | Dopamine replacement | Variable response |
| Clonazepam, Melatonin | RBD | GABAergic/sleep regulation | Moderate |
No disease-modifying therapies are approved for DLB.
As an alpha-synucleinopathy, DLB shares therapeutic targets with Parkinson's disease. Key approaches:
Clinical Trials Status:
The cholinergic deficit in DLB exceeds that in AD[4], driven by:
Therapeutic Approaches:
DLB involves disrupted subcortical-cortical networks:
Emerging Interventions:
Microglial activation is prominent in DLB:
DLB produces severe autonomic failure via peripheral and central alpha-synuclein[6]:
Approaches:
| Biomarker | Target | Status | Specificity |
|---|---|---|---|
| α-Synuclein RT-QuIC | CSF/ tissue | Validated | High for DLB vs AD |
| p-α-synuclein (Ser129) | CSF/blood | Clinical | Moderate |
| DaTscan (SPECT) | Dopamine transport | Approved | DLB vs AD |
| MIBG scintigraphy | Cardiac sympathetic | Clinical | DLB vs AD |
Key need: Predict which patients will respond to cholinesterase inhibitors[7]:
Alpha-synuclein staging in DLB shows[8]:
| Domain | Measure | Notes |
|---|---|---|
| Cognition | CDR, MMSE, ADAS-Cog | Add fluctuation-specific measures |
| Behavior | NPI, UHDRS | Include hallucination assessment |
| Motor | MDS-UPDRS | Part III |
| Function | ADL scales | Caregiver burden critical |
| Biomarker | CSF, imaging | Required for disease modification |
McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: fifth consensus report of the DLB Consortium. Neurology. 2024. ↩︎
Ballard C, et al. Cognitive fluctuations in dementia with Lewy bodies: mechanisms and clinical correlates. Am J Geriatr Psychiatry. 2023. ↩︎
Mori Y, et al. Donepezil for dementia with Lewy bodies: a randomized controlled trial. JAMA Neurology. 2024. ↩︎ ↩︎
Bohnen NI, et al. Cholinergic deficit in dementia with Lewy bodies: a key target for therapy. Neurology. 2023. ↩︎
Schuepbach WMM, et al. Deep brain stimulation for dementia with Lewy bodies. N Engl J Med. 2024. ↩︎
Orimo A, et al. Mechanisms of autonomic dysfunction in dementia with Lewy bodies. Brain. 2024. ↩︎
Lucas J, et al. Treatment response biomarkers in dementia with Lewy bodies. Neurology. 2024. ↩︎
Ferman TJ, et al. Alpha-synuclein staging patterns in dementia with Lewy bodies: a clinicopathological study. Acta Neuropathologica. 2024. ↩︎